A.S.S. (Alexander) Dömling, Prof Dr
Professor and chair Drug Design Group
Telephone:
E-mail:
a.s.s.domling rug.nl
Field/Discipline
Expertise
D
ö
mling belongs to top 2% of most influential researchers worldwide (Stanford-Elsevier https://elsevier.digitalcommonsdata.com/datasets/btchxktzyw/3 ). Multicomponent reaction chemistry, drug design & early development, structure-based drug design, fragment based drug design, computational drug design, proteases, protein protein interactions, receptors, missmutation, orphan disease, inflammation, cancer, metabolic disease
Other positions
Member of the faculty committee “Healthy Aging”
NWO-CW-FW study group director
Coordinator of MCB seminar series 2013/2014/2015
Cofounder of Carmolex Inc
Cofounder of Carmolex BV
Cofounder of Novel Therapeutics BV
Cofounder of Telesis Pharma BV
NWO-CW-FW study group director
Coordinator of MCB seminar series 2013/2014/2015
Cofounder of Carmolex Inc
Cofounder of Carmolex BV
Cofounder of Novel Therapeutics BV
Cofounder of Telesis Pharma BV
| Last modified: | 25 June 2022 12.20 a.m. |